EP: 5.CLEAR Trial: Len + Pembro or Everolimus vs Sunitinib EP: 6.Safety Profile of Len + Pembro From CLEAR in mRCC EP: 7.Dosing Strategies for Maximum Efficacy With Len + Pembro EP: 8.Using TKI/IO Combinations in Patients With mRCC EP: 9.Promising Studies for the Future of Front...
9559#Background:PD-1 inhibitors such as pembro are a standard-of-care option for advanced melanoma, and effective treatments are needed for disease that progresses on anti–PD-(L)1–based therapy. Previous results from the single-arm, open-label, phase 2 LEAP-004 study (NCT03776136) showed...
背景:全球、随机、双盲、III期LEAP-002研究(NCT03713593)评估了仑伐替尼联合帕博利珠单抗(lenva + pembro)对比仑伐替尼(lenva)+安慰剂作为aHCC 一线治疗的疗效和安全性。 方法:符合入组条件的aHCC患者按1:1随机分配至lenva(体重<60 kg的患者为8 mg/天;体重≥60 kg的患者为12 mg/天)联合pembro(200mg IV ...
Conclusions The LEN + PEMBRO combination showed promising antitumor activity in metastatic EC regardless of MSI/MMR status. Treatment was generally well tolerated, and no new safety signals emerged. A phase 3 study in advanced EC is underway (NCT03517449). Table: 994OInvestigator assessment per ir...
9504 Background: Initial results of the open-label, single-arm, phase 2 LEAP-004 study (NCT03776136) showed that len and pembro in combination had promising efficacy and manageable safety in pts with unresectable stage III-IV melanoma and confirmed PD on a PD-(L)1 inhibitor given alone or...
Dosing Strategies for Maximum Efficacy With Len + Pembro EP: 8.Using TKI/IO Combinations in Patients With mRCC EP: 9.Promising Studies for the Future of Frontline mRCCRobert J. Motzer, MD: Tom, you’ve used lenvatinib for over a decade and are probably 1 of the heaviest users of ...
Correlative serum biomarker analyses: Lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase Ib/II trial in advanced renal cell carcinoma (RCC)doi:10.1016/j.annonc.2020.08.791C-H. LeeY. AdachiH. IkezawaS.D. LiR.J. MotzerAnnals of Oncology...
搞错了,LEAP 008不是头对头K药。randomized 4:4:1 to len 20 mg/d QD PO plus ≤35 cycles of pembro 200 mg Q3W IV, doce 75 mg/m2 Q3W IV, or len 24 mg/d QD PO.
A phase 3 trial (LEAP-002; NCT03713593) is ongoing to assess LEN + PEMBRO vs LEN alone as first-line therapy for pts with uHCC. Table:747PResponse Parameter, n (%)LEN + PEMBRO (n=67)mRECIST Per InvestigatorORR (CR + PR + unconfirmed PR or CR)a Best Overall ResponseCR.PRaStable ...